Gaucher Disease Trial, Recruiting NCT02437396 Sponsor: University of Minnesota Condition: Gaucher Disease
Back to Gaucher Disease

Gaucher Disease Trial, Recruiting

NCT02437396
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older.
  • You must be able to understand what the study involves, be willing to follow its requirements, and sign a consent form agreeing to take part.
  • You must have Gaucher disease and be considered healthy enough to participate, in the opinion of the study doctor.
  • If you are on a specific enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for Gaucher disease, you must have been on the same treatment at the same dose for at least 2 years — or you must not have had any such treatment for at least 2 years.
  • If you have Type 1 Gaucher disease and recently changed your dose or switched to a different medication, you may still be able to join if at least 6 months have passed since that change and your doctor considers you stable.
  • You must not have taken the supplements coenzyme Q-10, vitamin C, or vitamin E for at least 3 weeks before joining the study.

Who may not be able to join:

  • You may not be able to join if you have an unstable medical condition, as judged by the study doctors.
  • You may not be able to join if you have another illness or situation that the study doctor believes could put you at risk or affect the quality of the study.
  • You may not be able to join if you are pregnant, breastfeeding, or could become pregnant and are not using an accepted form of contraception.
  • You may not be able to join if you currently have asthma that requires treatment.
  • You may not be able to join if you are unable or unwilling to have blood drawn.
  • You may not be able to join if you are unable or unwilling to follow the study schedule and requirements for any reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Reena Kartha, PhD, University of Minnesota

Phone: 612-626-2436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 October 2015
Est. completion
30 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Plasma C5a Concentration; Change in Plasma Hepcidin Concentration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov